Sanofi (SNYNF) has entered into a licensing agreement with RadioMedix and Orano Med to develop a next-generation radioligand treatment targeting rare cancers.
This collaboration will concentrate on AlphaMedix (212Pb-DOTAMTATE), a late-stage project currently being trialed for the treatment of adult patients with unresectable or metastatic, progressive somatostatin-receptor expressing neuroendocrine tumors (NETs), which are classified as rare cancers.
AlphaMedix is an advanced targeted alpha therapy that uses a somatostatin receptor-targeting peptide complex radiolabeled with lead-212 (212Pb). This configuration allows AlphaMedix to act as an in vivo generator of alpha particles.
According to the licensing agreement, Sanofi will undertake the global commercialization of AlphaMedix. Meanwhile, Orano Med will handle the manufacturing process through its developing global industrial platform.
Under the terms of the deal, RadioMedix and Orano Med will receive an upfront payment of 100 million euros and could earn up to an additional 220 million euros in sales milestones. They will also be eligible for tiered royalties. The agreement is contingent on obtaining the standard regulatory approvals necessary for such transactions.
